A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma

Plain Language Summary: What is this summary about? This summary presents the 7-year study results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) combined (COMBO group) against encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called locally advanced or metastatic BRAF V600-mutant melanoma. What were the results? More participants in the COMBO group were alive for longer and without their disease getting worse after 7 years than those in the VEMU group. Among participants who switched to a new anticancer treatment, those in the COMBO group lived longer than those in the VEMU or ENCO groups. What do the results of the study mean? This confirms that people with BRAF V600-mutant melanoma treated with encorafenib plus binimetinib or encorafenib alone lived longer than those treated with vemurafenib. This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text.